CN EN

Immunotherapy

Immunotherapy

Scroll

Immunotherapy
CAPRI Cells

Cascade Primed Immune Cells

CAPRI cells (Cascade Primed Immune Cells, the immune cells with chain activation) were developed by Prof Dr. Med Rudolf Wank, Institute of Immunology, University of Munich, Germany, and they are used in biotherapies for cancers as a patented technology (International Patent No.: WO 02/087612 A2, German Patent No.: DE10120505 A1, Japanese Patent No.: JP2004526795 T, U.S. Patent No.: US2004082065 A1, Chinese Patent No.: ZL 2016 1 0067151. 8). In CAPRI cell therapy, patient’s own peripheral blood mononuclear cells (PBMC) are used; through activation and stimulation cells with tumor-specific killing capability are yielded, and then the cells are infused back into the patient's body to kill tumor cells. According to the more than ten years of clinical observations in Germany, a combination therapy of CAPRI cell therapy with conventional therapies such as radiotherapy and chemotherapy can prolong survival of cancer patients and improve the quality of life. In Germany, CAPRI cell therapy has been used in combination with conventional therapies to treat lung cancer, breast cancer, colon cancer, non-Hodgkin lymphoma, gastric cancer, brain tumor, ovarian cancer, prostate cancer and other tumors, and the clinical efficacy was good.

Cell therapy is an important part of modern cancer treatments. In the existing methods, genetically engineered cancer polypeptides are used to induce T lymphocytes against corresponding tumor antigens, cytokine-induced killer cells (CIK), dendritic cells (DC), and so on.

FAQs about CAPRI Cell Therapy

Problem solving More

Reasons for Why Other Cell Therapies have failed to Achieve the Desired Effects

  • 01

    Being Difficult to Identify Antigens

    It is difficult in any cancer patients to determine which tumor cell surface antigen is capable of inducing immune reaction and immune response.

  • 02

    Tumor Cells Metastasize Frequently

    Even if the antigen capable of inducing immune reaction and immune response is identified, the problem is still not solved from its root. The reasons are as follows: tumor cells often selectively lose tumor-specific antigens, and the tumor cell surface antigens are even different for carcinoma in situ and metastatic carcinoma, which has been confirmed by research studies.

  • 03

    Tumor Cells Can Produce Cytokines

    Tumor cells can locally produce cytokines to reduce the tumor-killing capability of effector cells, so the efficacy of these therapies is impaired.

  • 04

    Insufficient Stimulators

    In the process of killing tumor cells by immune response, a large number of cytokines are required to participate in the process and stimulate immune responses. However, these stimulators are inadequate in patients who receive these therapies, so it is difficult to achieve the desired tumor-killing effect.

SOLUTION

Prof Dr. Med Rudolf Wank invented CAPRI cells by using peripheral blood mononuclear cells that have been stimulated via cascade priming

To solve these problems, Prof Dr. med Rudolf Wank invented CAPRI cells by using peripheral blood mononuclear cells that have been stimulated via cascade priming In CAPRI cell therapy, no matter how serious the loss of tumor cell antigens is, as long as there are still tumor antigens, the tumor-specific CAPRI cells can recognize the tumor antigens and kill them. In addition, some studies have confirmed that CAPRI cells can effectively increase the expression of tumor cell surface antigens, thus restoring the killing process of cytotoxic cells that has been blocked. CAPRI cells have the ability to recognize micrometastases, thereby preventing the occurrence of metastasis.

More advantage

Compared with the CIK cell therapy implemented in China, it has more advantages.

Compared with the CIK cell therapy implemented in China, it can be seen from the mechanism and the in vitro experiments that CAPRI cell therapy has obvious advantages; in CAPRI cell therapy, a large number of killer cells are included in the effector cells, and theoretically CAPRI cells can effectively kill tumor cells 100%.

However, CIK cells can only kill 20%-30% of the tumor cells. According to study results, under the same conditions, the tumor-killing capability of CAPRI cells is much higher than that of CIK cells. According to the more than ten years of clinical practice with CAPRI cell therapy in Germany, CAPRI cell therapy can prolong the life of patients and improve the quality of life.

CAPRI cells are activated autologous cells of the respective cancer patient, so they are very safe to use. According to the ten years’ experience in clinical application of CAPRI cells in Germany, the CAPRI cells provoke very little side effects: redness and swelling at the injection site in a few patients, which can almost be ignored.

Clinical Indications for CAPRI Cells

More than twenty solid tumors such as lung cancer, breast cancer, colon cancer, skin cancer, melanoma, ovarian cancer, gastric cancer, brain tumors, non-Hodgkin's lymphoma, prostate cancer, head and neck cancer (nasopharyngeal cancer, laryngeal cancer, oral squamous cell carcinoma, thyroid cancer, etc.), esophageal cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, endometrial cancer, gallbladder cancer, and most hematologic malignancies.

2019©LifeBank Biotech Co., Ltd.

Powered by SE